An antihypertensive agent that competitively inhibits angiotensin-converting enzyme (ACE; IC₅₀= 23-35 nM) and acts as a reversible and competitive inhibitor of LTA4 hydrolase (IC₅₀ = 11 µM).
An antihypertensive agent that competitively inhibits angiotensin-converting enzyme (ACE; IC50= 23-35 nM) and acts as a reversible and competitive inhibitor of LTA4 hydrolase (IC50 = 11 µM). Inhibits angiogenesis and slows the growth of experimental tumors in rats. Reported to inhibit apoptosis in human lung epithelial cells (IC50 = ~ 320 nM).
An antihypertensive agent. Reversible and competitive inhibitor of LTA4 hydrolase (IC50 = 11 µM). Also a competitive inhibitor of angiotensin-converting enzyme (ACE). Inhibits angiogenesis and slows the growth of experimental tumors in rats.
生物化学的/生理学的作用
Cell permeable: no
Primary Target ACE
Product does not compete with ATP.
Reversible: yes
Target IC50: 23-35 nM against angiotensin-converting enzyme (ACE); 11 µM against LTA4 hydrolase; ~ 320 nM inhibiting apoptosis in human lung epithelial cells
警告
Toxicity: Carcinogenic / Teratogenic (D)
その他情報
Uhal, B.D., et al. 1998. Am. J. Physiol.275, L1013. Volpert, O.V., et al. 1996. J. Clin. Invest.98, 671. Voors, A.A., et al. 1995. J. Cardiovasc. Risk2, 413. Orning, L., et al. 1991. J. Biol. Chem. 266, 16507. Kostis, J. 1988. Am. Heart J. 116, 1591.
法的情報
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany